Therefore, through this real-world data (RWD) analysis, we aim to compare the impacts of a GnRH antagonist (degarelix) and GnRHa treatments (goserelin, leuprolide, triptorelin), on the CVD risk in patients with PCa and pre-existing CVD, using Taiwan National Health Insurance Research Data (NHIRD). Here, GNRH1 is linked to posterior cortical atrophy.